MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 122625 | Name: XEN-D0101

Description:

WARNING: This product is for research use only, not for human or veterinary use.

XEN-D0101 is an experimental drug that was developed to treat atrial fibrillation, Xention, a biopharmaceutical company based in Cambridge, England, created XEN-D0101 along with other ion channel-modulating drugs. XEN-D0101 is a selective antagonist of the voltage-gated potassium channel Kv1.5. Atrial fibrillation is the main focus of Xention’s drug development, as it is the most common cardiac arrhythmia (irregular heart beat) seen in patients.

Chemical Structure

XEN-D0101
XEN-D0101
CAS#N/A

Theoretical Analysis

MedKoo Cat#: 122625

Name: XEN-D0101

CAS#: N/A

Chemical Formula: C26H28N6O2S

Exact Mass: 488.2000

Molecular Weight: 488.61

Elemental Analysis: C, 63.91; H, 5.78; N, 17.20; O, 6.55; S, 6.56

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
XEN-D0101; XEN D0101; XEND0101
IUPAC/Chemical Name
N-(2-hydroxyethyl)-1-(5-phenyl-4-((pyridin-2-ylmethyl)amino)thieno[2,3-d]pyrimidin-2-yl)piperidine-3-carboxamide
InChi Key
ZVUSKJPRMYQKKI-UHFFFAOYSA-N
InChi Code
InChI=1S/C26H28N6O2S/c33-14-12-28-24(34)19-9-6-13-32(16-19)26-30-23(29-15-20-10-4-5-11-27-20)22-21(17-35-25(22)31-26)18-7-2-1-3-8-18/h1-5,7-8,10-11,17,19,33H,6,9,12-16H2,(H,28,34)(H,29,30,31)
SMILES Code
OCCNC(C(C1)CCCN1C2=NC(NCC3=CC=CC=N3)=C(C(C4=CC=CC=C4)=CS5)C5=N2)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 488.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ford J, Milnes J, Wettwer E, Christ T, Rogers M, Sutton K, Madge D, Virag L, Jost N, Horvath Z, Matschke K, Varro A, Ravens U. Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor. J Cardiovasc Pharmacol. 2013 May;61(5):408-15. doi: 10.1097/FJC.0b013e31828780eb. PMID: 23364608. 2: Árpádffy-Lovas T, Mohammed ASA, Naveed M, Koncz I, Baláti B, Bitay M, Jost N, Nagy N, Baczkó I, Virág L, Varró A. Species-dependent differences in the inhibition of various potassium currents and in their effects on repolarization in cardiac ventricular muscle. Can J Physiol Pharmacol. 2022 Sep 1;100(9):880-889. doi: 10.1139/cjpp-2022-0028. Epub 2022 Apr 20. PMID: 35442802. 3: Devalla HD, Schwach V, Ford JW, Milnes JT, El-Haou S, Jackson C, Gkatzis K, Elliott DA, Chuva de Sousa Lopes SM, Mummery CL, Verkerk AO, Passier R. Atrial- like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology. EMBO Mol Med. 2015 Apr;7(4):394-410. doi: 10.15252/emmm.201404757. PMID: 25700171; PMCID: PMC4403042.